Key facts
- This page summarizes Karl Anders O Harfstrand's Form 4 filing for PROTHENA CORP PUBLIC LTD CO (PRTA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 19 May 2023, 21:30.
Karl Anders O Harfstrand - 17 May 2023 Form 4 Insider Report for PROTHENA CORP PUBLIC LTD CO (PRTA)
- Reporting relationship
- Director
- Issuer ticker
- PRTA
- Reported as of
- 17 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 May 2023, 21:30:53 UTC
- Prior SEC filing
- 27 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael J. Malecek, as attorney-in-fact for Karl Anders O. Harfstrand
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Karl Anders O Harfstrand filed Form 4 for PROTHENA CORP PUBLIC LTD CO (PRTA) on 19 May 2023.
Change
- Previous filing in this sequence was filed on 27 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PRTA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 17 May 2023
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 15,000
- Exercise price
- $76.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2024 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.